Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17225
Corporate User License Price USD 750
Corporate User License Price INR 51675
Site License Price USD 500
Site License Price INR 34450
Request a Quote

Report Title

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX-1 and IFX-2. InflaRx operates in various research and development programs in life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.

InflaRx NV (IFRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

InflaRx NV, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

InflaRx Raises USD55 Million in Series D Financing 10

InflaRx Raises USD34 Million in Series C Venture Financing 11

InflaRx Raises Funds through Series B Financing Round 12

Partnerships 13

InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13

Equity Offering 14

InflaRx Raises USD117.3 Million in Public Offering of Shares 14

InflaRx Raises USD100 Million in IPO 16

InflaRx NV-Key Competitors 17

InflaRx NV-Key Employees 18

InflaRx NV-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

Financial Announcements 20

Aug 09, 2018: InflaRx reports second quarter 2018 financial & operating results 20

May 17, 2018: InflaRx Reports First Quarter 2018 Financial & Operating Results 21

Mar 29, 2018: InflaRx Full Year 2017 Financial & Operating Results 23

Corporate Communications 24

Feb 06, 2018: InflaRx Names Tony Gibney As Board Director 24

Jun 21, 2017: InflaRx Promotes Othmar Zenker, M.D. to Newly Created Position of Chief Medical Officer 25

Clinical Trials 26

Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa 26

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa 27

Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa 28

Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

InflaRx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

InflaRx NV, Deals By Therapy Area, 2012 to YTD 2018 8

InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

InflaRx Raises USD55 Million in Series D Financing 10

InflaRx Raises USD34 Million in Series C Venture Financing 11

InflaRx Raises Funds through Series B Financing Round 12

InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13

InflaRx Raises USD117.3 Million in Public Offering of Shares 14

InflaRx Raises USD100 Million in IPO 16

InflaRx NV, Key Competitors 17

InflaRx NV, Key Employees 18

InflaRx NV, Other Locations 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

InflaRx NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person